HALUK YUZUGULLU

Citata da

	Tutte	Dal 2019
Citazioni	3041	1862
Indice H	12	11
i10-index	12	11

400

200

100

300

20102011201220132014201520162017201820192020202120222023202419 32 42 46 62 119 222 277 324 386 371 395 351 263 96

Accesso pubblico

Visualizza tutto

8 articoli

0 articoli

Disponibili

Non disponibili

In base ai mandati di finanziamento

Coautori

Mehmet OzturkIzmir Tinaztepe UniversityEmail verificata su tinaztepe.edu.tr
Serif SenturkProfessor at Dokuz Eylul University & Group Leader at Izmir Biomedicine and Genome CenterEmail verificata su ibg.edu.tr
Ozge gursoy YuzugulluDana Farber Cancer Institute, Harvard Medical SchoolEmail verificata su dfci.harvard.edu
Nuri OzturkProfessor @ Gebze Technical UniversityEmail verificata su gtu.edu.tr
Adam C PalmerAssistant Professor, UNC-Chapel HillEmail verificata su unc.edu
Wei LiChildren's National Hospital, George Washington UniversityEmail verificata su childrensnational.org
Xiaole Shirley LiuCEO, GV20 TherapeuticsEmail verificata su ds.dfci.harvard.edu
Ayça Arslan ErgülUNAM, Bilkent UniversityEmail verificata su bilkent.edu.tr
Richard YoungProfessor of Biology, MITEmail verificata su wi.mit.edu
Daniel G. StoverOhio State University Comprehensive Cancer CenterEmail verificata su osumc.edu
Kira GritsmanAlbert Einstein College of MedicineEmail verificata su einsteinmed.org
Cigdem Ozen, Ph.D.TU Dresden, Bioinformatics, Center for Molecular and Cellular Bioengineering (CMCB)Email verificata su tu-dresden.de
Hilal Ozdag PhDAnkara University Biotechnology InstituteEmail verificata su ankara.edu.tr
Rengul Cetin AtalayUniversity of ChicagoEmail verificata su uchicago.edu
nejat akarTOBB-ETU Medical School Pediatrics DepartmentEmail verificata su etu.edu.tr
Gokhan YildizKaradeniz Technical University School of Medicine Department of Medical BiologyEmail verificata su ktu.edu.tr
biter bilenPostdoctoral fellowEmail verificata su stanford.edu
Bala Gur DedeogluAnkara University Biotechnology InstituteEmail verificata su ankara.edu.tr
Isik G. YulugAssociate Professor of Molecular Biology and Genetics, Bilkent UniversityEmail verificata su fen.bilkent.edu.tr
Yongmin ChoiUniversity of Southern CaliforniaEmail verificata su usc.edu

Segui

HALUK YUZUGULLU

Astrazeneca Pharmaceuticals

Email verificata su astrazeneca.com

cancer stem cells breast cancer PDX leukemia liver cancer colorectal carcinoma


Titolo Ordina per citazioni Ordina per anno Ordina per titolo	Citata da Citata da	Anno
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting HYJJZ Lauren M. Thorpe Nature Reviews Cancer 15 (1), 7–24, 2014	1354*	2014
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors JJZ Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon ... Cancer Cell 29 (3), p255–269, 2016	427	2016
CDK7-dependent transcriptional addiction in triple-negative breast cancer Y Wang, T Zhang, N Kwiatkowski, BJ Abraham, TI Lee, S Xie, H Yuzugullu, ... Cell 163 (1), 174-186, 2015	417	2015
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells H Yuzugullu, K Benhaj, N Ozturk, S Senturk, E Celik, A Toylu, N Tasdemir, ... Molecular cancer 8, 1-20, 2009	304	2009
Senescence and immortality in hepatocellular carcinoma M Ozturk, A Arslan-Ergul, S Bagislar, S Senturk, H Yuzugullu Cancer letters 286 (1), 103-113, 2009	120	2009
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. SP Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE ... Cancer Cell 31 (4), 576–590, 2017	95	2017
Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation O Gursoy‐Yuzugullu, H Yuzugullu, M Yilmaz, M Ozturk Liver International 31 (4), 561-571, 2011	92	2011
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu, ... PloS one 8 (5), e64016, 2013	69	2013
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α K Gritsman, H Yuzugullu, T Von, H Yan, L Clayton, C Fritsch, SM Maira, ... The Journal of clinical investigation 124 (4), 1794-1809, 2014	65	2014
A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis H Yuzugullu, L Baitsch, T Von, A Steiner, H Tong, J Ni, LK Clayton, ... Nature communications 6 (1), 8501, 2015	47	2015
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity M Mumcuoglu, S Bagislar, H Yuzugullu, H Alotaibi, S Senturk, ... PloS one 5 (6), e11288, 2010	27	2010
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways H Yuzugullu, T Von, LM Thorpe, SR Walker, TM Roberts, DA Frank, ... Cell discovery 2 (1), 1-13, 2016	22	2016
Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma U Ekin, H Yuzugullu, C Ozen, P Korhan, E Bagirsakci, F Yilmaz, ... Journal of Gastrointestinal Cancer, 1-14, 2021	2	2021
Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly (ADP-ribose) polymerase (PARP … V Samnotra, V Moroz, L Shtessel, M Kuchimanchi, P Hanafin, ... Cancer Research 84 (7_Supplement), CT169-CT169, 2024		2024
Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer S Ghassemifar, Y Hashambhoy-Ramsay, H Yuzugullu, T Utermark, ... Cancer Research 79 (13), 2019		2019
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist D Tamara, S Ghassemifar, Y Hashambhoy-ramsay, DHC MARCANTONIO, ... US Patent App. 16/305,289, 2019		2019
INVESTIGATION OF CAUSATIVE AGENTS IN COMMUNITY-ACQUIRED ATYPICAL PNEUMONIA CASES E ÇALIŞKAN, Ş ÖKSÜZ, C ÖZTÜRK, I Sahin, O Kilincel, N Akar, ... FRESENIUS ENVIRONMENTAL BULLETIN 28 (5), 2019		2019
MM-161, a first-in-class pan-FGFR antibody T Dake, G Finn, M Geddie, N Kohli, M Razlog, L Xu, V Paragas, ... Cancer Research 77 (13_Supplement), 22-22, 2017		2017
Targeted Therapy for Hepatocellular Carcinoma: What`s New? H Yuzugullu, O Gursoy-Yuzugullu Liver Res Open J 1 (1), e1-e3, 2015		2015
PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten H Yuzugullu, L Baitsch, A Steiner, LK Clayton, K Gritsman, JJ Zhao Cancer Research 74 (19_Supplement), 4775-4775, 2014		2014

Il sistema al momento non può eseguire l'operazione. Riprova più tardi.

Articoli 1–20

Citazioni per anno

Citazioni duplicate

Citazioni unite

Aggiungi coautoriCoautori

Segui

Citata da

Coautori